# Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma

> **NCT03730740** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 79 (estimated)

## Conditions studied

- Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma

## Interventions

- **DRUG:** Lenalidomide 25mg

## Key facts

- **NCT ID:** NCT03730740
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-16
- **Primary completion:** 2021-11
- **Final completion:** 2023-11
- **Target enrollment:** 79 (ESTIMATED)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03730740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03730740, "Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03730740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*